Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Ư¹ß¼º ¸·¼º»ç±¸Ã¼½Åº´ÁõÀÇ ½Å»ç±¸Ã¼¿¡¼­ ¥á-Smooth Muscle Actin, Vimentin ¹ßÇö°ú ¿¹ÈÄ¿ÍÀÇ »ó°ü°ü°è Expression of Glomerular -Smooth Muscle Actin and Vimentin in Idiopathic Membranous Nephropathy as Prognostic Indicators

´ëÇѺ´¸®ÇÐȸÁö 2001³â 35±Ç 1È£ p.26 ~ 34
À̹ÎÁø, ±è¿Á°æ,
¼Ò¼Ó »ó¼¼Á¤º¸
À̹ÎÁø ( Lee Min-Jin ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

±è¿Á°æ ( Kim Ok-Kyung ) 
ÀÌÈ­¿©ÀÚ´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract


Background: The natural history of idiopathic membranous nephropathy (IMN) is heterogeneous with some patients showing spontaneous remission while others show a progressive course leading to end-stage renal failure. We tried to assess quantitatively -smooth muscle actin ( -SMA) and vimentin expression as markers to predict the outcome of membranous nephropathy.

Methods: This study included 24 patients with biopsy proven IMN. We measured the volume of the positive area for -SMA and vimentin within the glomeruli and compared the results with 5 patients in the normal control group. We evaluated glomerular -SMA and vimentin expression in correlation with BUN and serum creatinine level at the time of diagnosis and after treatment.

Results: Glomerular -SMA and vimentin in IMN were higher than in the control group. Glomerular -SMA was significantly higher in progressive IMN than in non-progressive IMN. The glomerular -SMA was sifnificantly correlated with BUN and serum creatinine at last follow-up (p<0.05), but there was no statistically significant correlation at diagnosis. The glomerular vimentin was not different between progressive and non-progressive groups.

Conclusion: These data suggest that the expression of glomerular -SMA may be a useful prognostic indicator and may be able to differentiate between patients with membranous nephropathy who respond well to treatment and those who continue to progress.

Å°¿öµå

Idiopathic membranous nephropathy;Prognosis;Morphometry;¥á-Smooth muscle actin;Vimentin

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS